Document Detail


Activation of the canonical Wnt/β-catenin signalling pathway is rare in canine malignant melanoma tissue and cell lines.
MedLine Citation:
PMID:  22901430     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Canine malignant melanoma is a highly aggressive tumour associated with a poor overall survival rate due to both local disease recurrence and its highly metastatic nature. Similar to advanced melanoma in man, canine oral melanoma is poorly responsive to conventional anti-cancer therapies. The lack of sustainable disease control warrants investigation of novel therapies, preferably targeting features specific to the tumour and different from normal cells. The Wnt signalling pathway is known to contribute to melanocytic lineage development in vertebrates and perturbation of the Wnt/β-catenin pathway has been implicated in numerous cancer types. Alterations of the Wnt/β-catenin pathway are suggested to occur in a subset of human melanomas, although the precise role of the Wnt/β-catenin pathway in melanoma is yet to be defined. This study investigates the activation status of the canonical Wnt/β-catenin pathway in canine malignant melanoma and its potential as a therapeutic target for treating this disease. The data indicate that canonical Wnt/β-catenin pathway activation is a rare event in canine oral malignant melanoma tissue and canine malignant melanoma cell lines.
Authors:
E Chon; V Thompson; S Schmid; T J Stein
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, N.I.H., Extramural     Date:  2012-08-14
Journal Detail:
Title:  Journal of comparative pathology     Volume:  148     ISSN:  1532-3129     ISO Abbreviation:  J. Comp. Pathol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-03-18     Completed Date:  2013-09-25     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  0102444     Medline TA:  J Comp Pathol     Country:  England    
Other Details:
Languages:  eng     Pagination:  178-87     Citation Subset:  IM    
Copyright Information:
Published by Elsevier Ltd.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / therapeutic use
Cell Line, Tumor
Disease Models, Animal
Dog Diseases / drug therapy,  pathology,  physiopathology*
Dogs
Humans
Melanoma / pathology,  physiopathology,  veterinary*
Mouth Neoplasms / pathology,  physiopathology,  veterinary*
Wnt Signaling Pathway / physiology*
beta Catenin / metabolism
Grant Support
ID/Acronym/Agency:
1UL1RR025011/RR/NCRR NIH HHS; KL2 RR025012/RR/NCRR NIH HHS; UL1 TR000427/TR/NCATS NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/beta Catenin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Urease and Helicobacter spp. Antigens in Pulmonary Granuloma.
Next Document:  The Great East Japan Earthquake of March 11, 2011, From the Vantage Point of Blood Banking and Trans...